Biotech Values

[DewDiligence]

PTLA—The last sentence of your post encapsulates the problem: A trial design that is marginally ok for a Big Pharma is not necessarily ok for a small biotech firm going it alone. As iwfal said, Betrixaban is going to be an “interesting” advisory panel. At even money, I would bet against a positive vote.

You didn’t comment on the other two bullet points I cited in #msg-89329551. I would have expected you to criticize the spin PTLA is promulgating about Betrixaban’s purportedly superior PK for the indication in question.